tesamorelin retatrutide – Research Peptide Retatrutide (Reta GLP-3) - 99%+

Additional launches are expected by the end of 2025, with the goal of reducing cost pressures on both employers and members

Zheng, Z

BJPsych Open

Smaller microdoses may offer a lower-cost alternative to full doses

Gastrointestinal side effects are among the most commonly reported adverse reactions with GLP-1 receptor agonists, and acid reflux (gastro-oesophageal reflux) and heartburn feature prominently in patient experiences

Plaintiffs with objective medical testing, prolonged treatment, permanent impairment, or emergency medical intervention may also present stronger claims during settlement negotiations or trial proceedings